Get access

Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues

Authors


Correspondence: Prof. H.L.A. Janssen, MD PhD, Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, ‘s Gravendijkwal 230, room Ha 204, 3015 CE Rotterdam, The Netherlands.

E-mail: h.janssen@erasmusmc.nl

Summary

HBeAg seroconversion in HBV patients is considered an important event. We determined precore (PC) and base core promoter (BCP) mutations in 137 HBeAg-positive nucleos(t)ide analogues (NA) treated patients by INNO-LiPA HBV PreCore assay (Innogenetics). The majority of patients with nongenotype A had PC/BCP mutants present at baseline (P = 0.02). During 29 months of therapy, 45 patients achieved HBeAg seroconversion. Probability of HBeAg seroconversion was higher in patients with PC and/or BCP mutants (= 0.01). After HBeAg seroconversion, patients with BCP mutants had more HBeAg relapse (= 0.07), and PC mutants less often achieved HBV DNA < 2000 IU/mL (= 0.07).

Ancillary